XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%

MT Newswires Live

2025/08/06

XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.

Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.

Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.

DoveTree will hold exclusive global rights to develop and commercialize any resulting products.

XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557134474"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557134474\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557134474?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557134474","market":"us","top_or_hot":-1,"title":"XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%","media":"MT Newswires Live","content":"<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-06 12:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1617","symbol_name":"AI医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557134474","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557134474","pubTimestamp":1754452929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"XtalPi Holdings  finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1617":"AI医疗","BK1141":"生命科学工具和服务","02228":"晶泰控股"},"translate_title":"XtalPi与DoveTree敲定药物发现协议；股价飙升8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":0.9},"content_text":"XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}